This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
40
implanting CivaSheet for localized radiation dose delivery
NYU Langone Health
New York, New York, United States
RECRUITINGLocal Control Rate at 1 year
The local control rate in the region irradiated by CivaSheet.
Time frame: 1 year
Freedom from regional or distant recurrence
Control rate for recurrences outside the local area irradiated by CivaSheet.
Time frame: 1 year
Time to recurrence
Time in months to any recurrence
Time frame: 1 year
Toxicity graded on CTCAE 4.0 Scale
pulmonary function, radiation pneumonitis, fatigue, lung fibrosis, etc.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.